Skip to main content
SpringerLink
Log in

Manage the neuropsychiatric manifestations of systemic lupus erythematosus with mostly empirical treatments

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I

References

  1. Postal M, Costallat LTL, Appenzeller S. Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management. CNS Drugs 2011; 25(9): 721–36

    Article  PubMed  Google Scholar 

  2. Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010 Dec; 69(12): 2074–82

    Article  CAS  PubMed  Google Scholar 

  3. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999 Apr; 42(4): 599–608

    Article  Google Scholar 

  4. Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol 2010 Jun; 6(6): 358–67

    Article  PubMed  Google Scholar 

  5. Hanly JG, McCurdy G, Fougere L, et al. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 2004; 31(11): 2156–62

    Google Scholar 

  6. Hanly JG, Harrison MJ. Management of neuropsychiatric lupus. Best Pract Res Clin Rheumatol 2005 Oct; 19(5): 799–821

    Article  PubMed  Google Scholar 

  7. Sanna G, Bertolaccini ML, Mathieu A. Central nervous system lupus: a clinical approach to therapy. Lupus 2003; 12(12): 935–42

    Article  CAS  PubMed  Google Scholar 

  8. Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005 Apr; 64(4): 620–5

    Article  CAS  PubMed  Google Scholar 

  9. Heinlein AC, Gertner E. Marked inflammation in catastrophic longitudinal myelitis associated with systemic lupus erythematosus. Lupus 2007; 16(10): 823–6

    Article  CAS  PubMed  Google Scholar 

  10. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349(12): 1133–8

    Article  CAS  PubMed  Google Scholar 

  11. Mok CC, Lau CS, Wong RW. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. Am J Med 2003 Jul; 115(1): 59–62

    Article  CAS  PubMed  Google Scholar 

  12. Cuadrado MJ, Khamashta MA, Ballesteros A, et al. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore) 2000; 79(1): 57–68

    Article  CAS  Google Scholar 

  13. Bosma GP, Rood MJ, Zwinderman AH, et al. Evidence of central nervous system damage in patients with neuropsychiatric systemic lupus erythematosus, demonstrated by magnetization transfer imaging. Arthritis Rheum 2000; 43(1): 48–54

    Article  CAS  PubMed  Google Scholar 

  14. Ramos PC, Mendez MJ, Ames PR, et al. Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol 1996 May–Jun; 14(3): 295–9

    CAS  PubMed  Google Scholar 

  15. Xu J, Cheng Y, Chai P, et al. White-matter volume reduction and the protective effect of immunosuppressive therapy in systemic lupus erythematosus patients with normal appearance by conventional magnetic resonance imaging. J Rheumatol 2010 May; 37(5): 974–86

    Article  PubMed  Google Scholar 

  16. Valesini G, Priori R, Francia A, et al. Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate. Springer Semin Immunopathol 1994; 16(2–3): 313–21

    CAS  PubMed  Google Scholar 

  17. Dong Y, Zhang X, Tang F, et al. Intrathecal injection with methotrexate plus dexamethasone in the treatment of central nervous system involvement in systemic lupus erythematosus. Chin Med J (Engl) 2001 Jul; 114(7): 764–6

    CAS  Google Scholar 

  18. Grisanti M, Nader A, Cacciuttolo R. Central nervous system involvement due to systemic lupus erythematosus/antiphospholipid syndrome: successful treatment with mycophenolate mofetil. Lupus 2001; 10: S31

    Google Scholar 

  19. Schroeder JO, Euler HH. Treatment combining plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Adv Exp Med Biol 1989; 260: 203–13

    Article  CAS  PubMed  Google Scholar 

  20. Dall’Era M, Wofsy D. Biologic therapy for systemic lupus erythematosus. Discov Med 2010; 9(44): 20–3

    PubMed  Google Scholar 

  21. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010 Jan; 62(1): 222–33

    Article  CAS  PubMed  Google Scholar 

  22. Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol 2010 Jul; 29(7): 707–16

    Article  PubMed  Google Scholar 

  23. Turner-Stokes T, Lu TY, Ehrenstein MR, et al. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford) 2011 Aug; 50(8): 1401–8

    Article  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Manage the neuropsychiatric manifestations of systemic lupus erythematosus with mostly empirical treatments. Drugs Ther Perspect 28, 11–14 (2012). https://doi.org/10.2165/11208750-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11208750-000000000-00000

Search

Navigation